AI-generated · cited to primary sources · not investment advice
Marksans Pharma (524404) Aug 2025 Filing Analysis
Does management do what it says?
The company is working on changing its product mix to mitigate the impact of 20% tariffs on raw materials from China. — target: Mitigate 20% tariff impact
“So, we are working on the product mix to avoid that tariff implications on raw materials originating out of China. That will take another couple of months. So, definitely from the third quarter, you will see better bottom lines also coming from the U.S.”
See the full cited Management analysis of Marksans Pharma
How durable is the business?
The US market showed robust growth of 30.6% YoY, driven by new launches in digestive and pain management, despite seasonal softness and tariff-related front-loading of inventory. (1 expanding)
“Revenue from the U.S. and North America market stood at INR327.6 crores, an increase of 30.6% on a year-on year basis”
See the full cited Business Model analysis of Marksans Pharma
Where does growth come from?
Gross margins continue to show a steady upward trend, reaching 57.8% this quarter due to lower raw material costs and inventory liquidation. (2 steady across 2 signals)
“Gross margin expanded by 209 basis points from 55.7% to 57.8% in Q1 of FY '26. Gross margin improved due to liquidation of high-cost inventories and benefits from softening input costs.”
See the full cited Future Growth analysis of Marksans Pharma
What could break the thesis?
Concentration risk is intensifying due to geopolitical factors; specifically, US import tariffs on Chinese raw materials (20% tariff) are making US-based manufacturing more expensive than Indian manufacturing. (1 intensifying)
“We are paying a 20% tariffs on raw materials. So, basically, U.S. has become more expensive to manufacture in U.S. than in India.”
See the full cited Risk analysis of Marksans Pharma
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.